Skip to content

Comparison of different formula milk powder on improving the effect of Cognitive Dysfunction in Elderly Patients : A Randomized Controlled Study

Comparison of different formula milk powder on improving the effect of Cognitive Dysfunction in Elderly Patients : A Randomized Controlled Study

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1800015001
Enrollment
Unknown
Registered
2018-02-27
Start date
2017-10-11
Completion date
Unknown
Last updated
2018-03-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Mild cognitive impairment

Interventions

control group:milk powder
low dose group:milk powder
high dose group:milk powder

Sponsors

Shanghai Jiao Tong University Affiliated Sixth People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: (1) aged 45-85 years old healthy middle-aged and elderly people have the main memory of subjective memory decline; (2) memory loss course of more than 3 months, not meet the diagnostic criteria for dementia; (3) MMSE score: years of education = 6 years, then = 22 points; years of education> 6 years, = 26 points;

Exclusion criteria

Exclusion criteria: (1) taking nutritional supplements to improve cognitive function within three months prior to enrollment; (2) lactose intolerance; (3) severe liver and kidney disease, such as glomerulonephritis, nephrotic syndrome, cirrhosis, etc .; severe cardiovascular and cerebrovascular diseases; (4) Those who have a lower education level than junior middle school (5) smoking, alcoholism; (6) Those who have not signed the informed consent; (7) participated in other clinical trials within three months; (8) Persons with delirium, confusion, or other disabilities; (9) Cognitive decline caused by neurological disorders include Alzheimer's disease, Parkinson's disease, stroke, normal-pressure hydrocephalus and other brain lesions including tumors; (10) Infectious or inflammatory encephalopathy history; (11) major head injury caused by cognitive decline; (12) Beans, fish, seafood allergy.

Design outcomes

Primary

MeasureTime frame
acetylcholinesterase;SOD;MDA;

Secondary

MeasureTime frame
FFA;blood glucose;insulin;folic acid;VB12;homocysteine;TC;TG;HDL-C;LDL-C;

Countries

China

Contacts

Public ContactSheng Ge

Shanghai Jiao Tong University Affiliated Sixth People's Hospital

gesheng607@126.com+86 18930177508

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026